Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5071117 | 1.00 | LMNA (0.48) | LMNAKMT2AHPGDALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5069533 | 0.98 | LMNA (0.50) | LMNAKMT2AHPGDALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5071101 | 0.98 | LMNA (0.50) | LMNAKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL5014356 | 0.98 | LMNA (0.49) | LMNAKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL5069524 | 0.97 | LMNA (0.51) | LMNAKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL5071137 | 0.97 | LMNA (0.51) | LMNAKMT2AHPGDALDH1A1TSHR | |
| Bromide SCHEMBL3843780 | 0.97 | LMNA (0.51) | LMNAKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL5070436 | 0.97 | LMNA (0.51) | LMNAKMT2AHPGDALDH1A1TSHR | |
| Bromide SCHEMBL3846115 | 0.95 | LMNA (0.54) | LMNAKMT2AHPGDALDH1A1TSHR | |
| Bromide SCHEMBL3845782 | 0.95 | LMNA (0.54) | LMNAKMT2AHPGDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790859-B2 | THERAPY OR REDUCING PROGRESSION OF HYPERTENSION OR DAMAGE TO A TISSUE CAUSED BY CONTACT WITH ELEVATED LEVELS OF REDUCING SUGARS IN AN ANIMAL, COMPRISING ADMINISTERING TO THE ANIMAL AN EFFECTIVE AMOUNT OF THIAZOLIUM COMPOUNDS | ALTEON INCORPORATED | 2004-09-14 | — | — | US | disclosed |
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | SYNVISTA THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | AGER, OGA, PTMS | LMNA 1577/4885KMT2A 2454/4885HPGD 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.